Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 3/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867540 | 0.81 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL535964 | 0.78 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL21558601 | 0.75 | ERN1 (0.44) | ALDH1A1ERN1TYR | |
| SCHEMBL9220820 | 0.73 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL27661574 | 0.71 | MDM4 (0.31) | — | |
| SCHEMBL17529259 | 0.71 | ACHE (0.39) | TDP1ALDH1A1TSHRCA1CA2 | |
| SCHEMBL25484900 | 0.69 | GABRA1 (0.41) | LMNAKMT2AMEN1BLMTDP1 | |
| SCHEMBL19848617 | 0.68 | ADRA2A (0.32) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL7641571 | 0.67 | TDP1 (0.38) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL8054028 | 0.67 | IRAK4 (0.46) | ALDH1A1TSHRHPGDHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183382-B2 | ruthenium transition metal complexes used as cyclization catalyst | EVONIK DEGUSSA GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183382-B2 | ruthenium transition metal complexes used as cyclization catalyst | EVONIK DEGUSSA GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183382-B2 | ruthenium transition metal complexes used as cyclization catalyst | EVONIK DEGUSSA GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| EP-1990348-A2 | Metathesis catalysts containing sulphur | Evonik Degussa GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1990348-A2 | Metathesis catalysts containing sulphur | Evonik Degussa GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080275247-A1 | SULPHUR-CONTAINING METATHESIS CATALYSTS | EVONIK DEGUSSA GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275247-A1 | SULPHUR-CONTAINING METATHESIS CATALYSTS | EVONIK DEGUSSA GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275247-A1 | SULPHUR-CONTAINING METATHESIS CATALYSTS | EVONIK DEGUSSA GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275247-A1 | SULPHUR-CONTAINING METATHESIS CATALYSTS | TST, MPST, CBS | LMNA 4675/4885KMT2A 2911/4885MEN1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.